Demand for passenger automobiles was stronger than anticipated as soon as Covid-related lockdown restrictions have been lifted as a consequence of shift in desire in the direction of private mobility.
Product life cycle to enhance: Levers for margin restoration in place. The MSIL inventory has underperformed (27% v/s Nifty and 23% v/s NSE Auto Index) within the final six months, impacted by market share/loss and strain on margin, regardless of a powerful quantity restoration. We see each these issues abating as product life cycle improves, and worth improve/low cost moderation drives a restoration in profitability. We count on ~30% quantity progress in FY22E and optimistic evolution of margin. We see 27% upside at our TP of Rs 8,700/share. MSIL is our prime auto choose.
Demand for passenger automobiles was stronger than anticipated as soon as Covid-related lockdown restrictions have been lifted as a consequence of shift in desire in the direction of private mobility. This was mirrored in robust demand with first-time purchaser (FTB) share rising to 50% in FY21 YTD (from 45% in FY20) of home volumes. Home volumes for the trade have been increased than FY19 ranges (earlier peak) since Sep’20 onwards. Restoration within the PV demand would have been higher, however for a pointy rise in gas costs (~30% improve within the final eight months). This, resulted in a rise in gross sales of CNG automobiles.
Important gas worth inflation resulted in prospects preferring CNG automobiles as a consequence of considerably decrease operating prices (Rs 1.5/km v/s Rs 4.5/km for WagonR CNG v/s petrol). MSIL enjoys a considerable benefit in CNG because it presents manufacturing facility fitted CNG in eight fashions. MSIL’s CNG automobile gross sales are anticipated to develop by 47%/59% in FY21E/FY22E. MSIL gained essentially the most as a consequence of improve in demand from first-time consumers, pushed by its stronghold within the mini-segment (the place its market share elevated by ~5pp in FY21 YTD to ~84). Whereas we count on FTB share to normalise over the following six-nine months, new launches would offset any influence of this.